The collaboration will see e-Therapeutics combine its Network-Driven Drug Discovery (NDD) platform with C4XD's Taxonomy3 technology, which utilises genomes to identify new patient-specific targets, the company said in a statement.
Parkinson's Disease is a degenerative disorder of the central nervous system estimated to affect 10 million people worldwide.
No cure is available currently and the aim of the collaboration is to identify new treatment strategies, molecular targets and, ultimately, novel drugs.
Taxonomy3 has already identified 180 novel disease-associated genes for Parkinson’s and e-therapeutics will use its NDD platform to help understand how the cellular mechanisms interact in the pathology of the disease.
Ray Barlow, e-therapeutics’ chief executive, said there remains a significant unmet medical need for truly effective treatments for Parkinson’s Disease.
"Our aim is to use the genomic associations that C4XD's Taxonomy3 technology platform has uncovered, to create new therapeutic approaches to treat this devastating disease."
He added the group is also working on genome-based functionality for its NDD platform in other areas including triple negative breast cancer.
The financial terms of the agreement were not disclosed.